secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001937653-23-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports 44% reduction in nine-month net loss to $104.2M; launches ZW251 IND candidate for HCC
--------------------------------------------------------------------------------

- Nine-month net loss decreased 44% to $104.2M vs $185.1M same period 2022; revenue up 491% to $59.1M.
- Cash resources $390.2M as of Sept 30, 2023; expected to fund operations through at least end of 2026.
- ZW251, GPC3-targeted ADC for hepatocellular carcinoma, nominated as next IND candidate; filing expected 2H-2025.
- Zanidatamab partner BeiGene presented Phase 1b/2 data: ORR 75.8%, mDOR 22.8 months, mPFS 16.7 months in first-line HER2+ GEA.
- Termination of licensing agreement for zanidatamab zovodotin with BeiGene; Zymeworks regained APAC rights and plans Phase 2 study in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/0001937653-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/zyme-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001937653-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer